Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytosorbents (CTSO) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to -$3.2 million.

  • Cytosorbents' Consolidated Net Income fell 1452.31% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.4 million, marking a year-over-year increase of 1597.93%. This contributed to the annual value of -$20.7 million for FY2024, which is 2915.81% up from last year.
  • As of Q3 2025, Cytosorbents' Consolidated Net Income stood at -$3.2 million, which was down 1452.31% from -$4.2 million recorded in Q2 2025.
  • Cytosorbents' 5-year Consolidated Net Income high stood at -$766126.0 for Q4 2022, and its period low was -$12.2 million during Q3 2022.
  • Moreover, its 5-year median value for Consolidated Net Income was -$6.2 million (2023), whereas its average is -$6.1 million.
  • As far as peak fluctuations go, Cytosorbents' Consolidated Net Income crashed by 127327.47% in 2021, and later skyrocketed by 9176.83% in 2022.
  • Over the past 5 years, Cytosorbents' Consolidated Net Income (Quarter) stood at -$9.3 million in 2021, then soared by 91.77% to -$766126.0 in 2022, then crashed by 758.12% to -$6.6 million in 2023, then fell by 15.1% to -$7.6 million in 2024, then skyrocketed by 58.11% to -$3.2 million in 2025.
  • Its Consolidated Net Income stands at -$3.2 million for Q3 2025, versus -$4.2 million for Q2 2025 and -$1.5 million for Q1 2025.